Search Results - "Gelder, T"

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation by Shuker, N., Bouamar, R., Schaik, R. H. N., Clahsen‐van Groningen, M. C., Damman, J., Baan, C. C., Wetering, J., Rowshani, A. T., Weimar, W., Gelder, T., Hesselink, D. A.

“…Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This…”
Get full text

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized‐Controlled Clinical Trials by Bouamar, R., Shuker, N., Hesselink, D. A., Weimar, W., Ekberg, H., Kaplan, B., Bernasconi, C., Gelder, T.

“…Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration–effect relationship for Tac is poorly defined. This…”
Get full text

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs by van Leeuwen, R W F, Brundel, D H S, Neef, C, van Gelder, T, Mathijssen, R H J, Burger, D M, Jansman, F G A

“…Background: Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment…”
Get full text

The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial by Abdulla, A, Ewoldt, T M J, Hunfeld, N G M, Muller, A E, Rietdijk, W J R, Polinder, S, van Gelder, T, Endeman, H, Koch, B C P

“…Critically ill patients undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics. Up to 60% of intensive care unit…”
Get full text

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients by Andrews, L. M., Hesselink, D. A., Schaik, R. H. N., Gelder, T., Fijter, J. W., Lloberas, N., Elens, L., Moes, D. J. A. R., Winter, B. C. M.

“…Aims The aims of this study were to describe the pharmacokinetics of tacrolimus immediately after kidney transplantation, and to develop a clinical tool for…”
Get full text

Mycophenolate Blood Level Monitoring: Recent Progress by Van Gelder, T.

“…The concentration–effect relationship for mycophenolic acid (MPA), and the high variability in MPA concentrations in patients on standard dose mycophenolate…”
Get full text

Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions by van Leeuwen, R.W.F., Jansman, F.G.A., van den Bemt, P.M.L.A., de Man, F., Piran, F., Vincenten, I., Jager, A., Rijneveld, A.W., Brugma, J.D., Mathijssen, R.H.J., van Gelder, T.

“…Drug interactions are of major concern, since cancer patients take many medications and may have serious consequences. Therefore, a study was designed to…”
Get full text

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations by Tang, J T, Andrews, L M, van Gelder, T, Shi, Y Y, van Schaik, R H N, Wang, L L, Hesselink, D A

“…Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and…”
Get more information

A fast and sensitive LC–MS/MS method for the quantification of fosfomycin in human urine and plasma using one sample preparation method and HILIC chromatography by Wijma, Rixt A., Bahmany, Soma, Wilms, E.B., van Gelder, T., Mouton, Johan W., Koch, Birgit C.P.

“…•Fosfomycin is gaining popularity in antibiotic prescription.•Analysis of urine and plasma concentrations is needed for PK/PD characterization.•PK/PD of…”
Get full text

High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers by Wijma, R.A., Koch, B.C.P., van Gelder, T., Mouton, J.W.

“…Fosfomycin is increasingly being prescribed for treatment of uncomplicated urinary tract infections in an era of emerging drug resistance. Surprisingly, little…”
Get full text

Therapeutic Drug Monitoring for Mycophenolic Acid Is Value for (Little) Money by Gelder, T

Get full text

Drug–drug interactions in pediatric oncology patients by Balk, T. E., der Sijs, I. H., Gelder, T., Janssen, J. J. B., der Sluis, I. M., Leeuwen, R. W. F., Engels, F. K.

“…Background Drug–drug interactions (DDIs) can negatively affect pharmacotherapy. However, pediatric DDI studies are scarce. We undertook an exploratory study to…”
Get full text

Lessons learned from conducting a randomized controlled trial to improve non-adherence to antihypertensive drug treatment by Peeters, L.E.J., van Gelder, T., van Dijk, L., Koch, B.C.P., Versmissen, J.

“…PURPOSEHypertension significantly contributes to cardiovascular diseases and premature deaths. Effective treatment is crucial to reduce cardiovascular risks,…”
Get full text

Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome? by Gelder, T, Hesselink, D A

“…Tacrolimus, widely used to prevent acute rejection following solid‐organ transplantation, has become the cornerstone of immunosuppressive therapy after kidney…”
Get full text

Individualization of Tamoxifen Treatment for Breast Carcinoma by Binkhorst, L, van Gelder, T, Mathijssen, R H J

“…Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6…”
Get full text

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer by Souwer, E. T. D., Sanchez-Spitman, A., Moes, D. J. A. R., Gelderblom, H., Swen, J. J., Portielje, J. E. A., Guchelaar, H. J., van Gelder, T.

“…Background We aimed to study the pharmacokinetics and -dynamics of tamoxifen in older women with non-metastatic breast cancer. Methods Data for this analysis…”
Get full text

Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice by van Westrhenen, R, van Schaik, R H N, van Gelder, T, Birkenhager, T K, Bakker, P R, Houwink, E J F, Bet, P M, Hoogendijk, W J G, van Weelden-Hulshof, M J M

“…Effective pharmacologic treatments for psychiatric disorders are available, but their effect is limited due to patients' genetic heterogeneity and low…”
Get full text

Personalized immunosuppression in elderly renal transplant recipients by Peeters, L.E.J., Andrews, L.M., Hesselink, D.A., de Winter, B.C.M., van Gelder, T.

“…[Display omitted] The number of elderly people has increased considerably over the last decades, due to a rising life expectancy and ageing populations. As a…”
Get full text

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial by Peeters, Laura E J, Kappers, M H W, Hesselink, D A, van der Net, J B, Hartong, S C C, van de Laar, R, Ezzahti, M, van de Ven, P J G, van der Meer, I M, de Bruijne, E L E, Kroon, A A, Indhirajanti-Tomasoa, S, van der Linde, N A J, Bahmany, S, Boersma, E, Massey, E K, van Dijk, L, van Gelder, T, Koch, Birgit C P, Versmissen, Jorie

“…Adherence to antihypertensive drugs (AHDs) is crucial for controlling blood pressure (BP). We aimed to determine the effectiveness of measuring AHD…”
Get full text

UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients by Schaik, R H N, Agteren, M, Fijter, J W, Hartmann, A, Schmidt, J, Budde, K, Kuypers, D, Le Meur, Y, Werf, M, Mamelok, R, Gelder, T

“…Mycophenolate mofetil (MMF) is an immunosuppressive drug commonly used in the context of kidney transplantation. Exposure to the active metabolite mycophenolic…”
Get full text